Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

Market Cap	6.04B -1.6%
Revenue (ttm)	1.14B -2.3%
Net Income	228.68M -8.6%
EPS	1.01 -8.6%
Shares Out	226.80M
PE Ratio	26.42
Forward PE	n/a
Dividend	0.20 (0.74%)
Ex-Dividend Date	Jul 17, 2025

Volume	1,787,300
Average Volume	2,159,482
Open	27.02
Previous Close	27.02
Day's Range	26.55 - 27.05
52-Week Range	25.03 - 33.79
Beta	0.40
RSI	41.18
Earnings Date	Apr 27, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 198...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1985
• Employees: 859
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002880

Financial Performance

In 2024, SHE:002880's revenue was 1.20 billion, an increase of 14.75% compared to the previous year's 1.05 billion. Earnings were 253.52 million, an increase of 15.95%.